The Upstream Elimination Race Is Not About Price. It Is About Judgement

By the tenth certificate I had gone numb. We will have a full dozen soon enough.

People keep asking me: is there still an opportunity here?

Yes, and no.

Yes, because the market always holds structural vacancies;

no, because the threshold of judgement and capability in this industry has finally begun to rise.

This industry’s story has moved on from opportunism and window-of-opportunity gains into an era of collapsing trust, a broken talent pipeline, rampant short-termism and open price wars.

What does opportunity actually mean here?

A hundred million in sales on the books in three months?

A distributor sitting on more than half their stock and someone still willing to take the line on?

A team with 50% annual attrition still managing to grow?

Or a false high price propped up by rebates and subsidies?

Yes, there is still room in penetration, lower-tier markets are not saturated, trust in tier-one and tier-two cities can still be improved, and the niches remain thin.

New clinic openings and new channel sign-ups — the first growth curve — matter, of course. But the second growth curve, the second and third waves of repeat purchase that sit at the heart of this business, is where the structural reshuffle begins.

Channels will start clearing inventory, companies will realise how much brand strength matters, and clear tiers of talent will emerge inside teams.

The elimination race upstream will not come with formal closures and reopenings. The landscape will simply be reshaped, quietly.

On the surface, prices for the latest round of injectables keep sliding.

Some create the price gap through dose, concentration and particle size;

some run soft discounts through pre-sale offers and inflated credit;

some simply cut hard, taking a product six months from launch down to 30% of list.

The price war is only smoke on the surface.

The real watershed is the gap in judgement:

a low price is not the problem;

the problem is whether a company can think through the system logic that supports the low price.

A company with a system knows why it can be cheap, how cheap it can go, and for how long;

a company without one simply follows, passively, as prices keep falling.

A price war cannot end in victory for a single SKU.

This is genuinely hard to call. Some companies perform at the low end of the industry today and yet, having entered early and accumulated the dividends of their era, still have the strength and the chance to cross the cycle.

For new entrants, though, the difference in fate between companies is rarely accidental. It is the outcome the business model dictated. As the industry lifts its standards and clears the field, four types are the classic structural traps.

Type one: under-funded.

Cash flow is tight, and the hope is that the first round of collections will fund marketing.

In the main Class III arena, companies like this are usually stretched thin, focused on short-term sell-through numbers and neglecting strategic balance.

And when results disappoint, as they very often do, continuing market investment is constrained and the vicious circle sets in.

Type two: pure price war.

Able to obtain a certificate, but lacking any capability in market development.

Under market pressure or cash-flow pressure, these companies tend to choose low pricing or white-label from the start, or let prices diverge chaotically across channels.

They are quickly put on the back foot region by region,

and a lucky few may find support from a distributor or an outsourced operator.

Most likely they flower briefly, are abandoned by the mainstream market, get typecast as a white-label factory, and find that later products carry no market confidence either.

Type three: illusory innovation.

The same Class III certificate can sit on very different technical foundations.

Some companies cannot even explain the conditions of a basic viscoelasticity test,

pixelate their particle-size reports,

deliberately avoid basic D50/D70/D90 data,

put out hollow talking points and operating plans copied from one another,

and leave clinical outcome to imagination and safety to luck.

The so-called new product is new packaging and a new name.

Products with no clinical strength and no safety evidence behind them,

relying purely on hype and misdirection — if that can succeed long-term in medical aesthetics, it is a tragedy for the industry.

Type four: no team behind it.

For one reason or another, the company treats staff as consumables, cannot hire for long stretches, or has extraordinary turnover.

Every new director or manager who arrives changes the strategy, changes the suppliers, changes the team,

three to five times a year.

Money and resources are there; organisational capability is not.

This industry is small, word travels fast, and market confidence collapses into a wait-and-see stance quickly.

Trust is the scarcest and most valuable asset in medical aesthetics.

That holds for consumers, and equally for clinics and channels.

Once trust is spent in advance, the product and the brand both become short-lived traffic.

On the subject of competitiveness: the divergence among upstream companies is, in essence, a divergence in the judgement of their founders.

Judgement is not the information you get from reading a few more industry accounts, talking to a few more experts, or attending a few more conferences.

It is the capacity, amid complexity and noise, to move beyond awareness into acknowledgement and judgement.

That capacity determines how a company chooses its track, allocates resources, builds a team and reads a signal.

Judgement is where every strategy starts.

Strategic judgement: read the industry’s direction without following blindly

Following is a perfectly good strategy in itself, but once too many people follow, only the top three win.

Capital has cooled, and companies and media accounts alike need to think rather than be pulled along by surface heat.

Instead of watching whose material sells dearest and whose margin is fattest and piling in behind them,

pay more attention to international trends and new materials, talk more with clinicians about clinical needs and treatment feedback, look harder at what consumers actually struggle with…

Bear a period of quiet, and position for the tracks whose window opens later.

Commercial judgement: cultivate genuine differentiation

Do not be seduced into this industry by its false prosperity.

Be clear about which money you want to earn and what advantage you hold.

Capital advantage, material advantage, cost advantage, brand advantage, channel advantage, talent advantage, expert advantage…

Prepare your thinking thoroughly.

With none of it in place, you get one harvest at most.

Brand judgement: taste is judgement made visible

Taste is not just a founder’s appetite for premium brands. Behind the judging lies an understanding of brand character.

Whether something looks good is a matter of opinion, but the core of brand character in this industry is consistency, stability and continuity.

Tone of voice, packaging, scientific communication, physician conversations — all of it should speak one language.

The small reveals the large. Taste is a founder’s grasp of brand order, the sense of where a brand’s quality begins and ends.

A brand does not mean expensive, and does not mean burning money. Attend to the details of your brand assets and spend the money on the customers who buy your product; people will see it.

Organisational judgement: build a team, do not pile up acquaintances

A good team is assembled by structural fit, not stacked from people you happen to know.

Whether a founder can tell capable people from well-matched people decides whether the company can hold steady from the start.

How far a founder can see decides how far a team can go.

Going from zero to one, a small company does not need much organisational structure, and plenty of owners manage by mood.

Moving towards stability and maturity, understanding organisation is an enormous threshold.

Partnership judgement: treat the channel as a partner, not a crop to harvest

Distributors, physicians, clinics, media — these are not resources. They are the industry’s ecosystem.

An ecosystem requires shared gain and shared upkeep.

Trust is the scarcest asset in medical aesthetics.

Anyone still using heavy deposits, absurd minimum orders, targets detached from reality, high-dose injection protocols and recklessly promised channel prices should know: harvest once and the market does not come back a second time.

And the company then spends twice the effort untangling channels, managing prices, swapping and reallocating stock, and handling complaints.

This business is about accompaniment, about shared gain, about the partnership judgement that lets the whole ecosystem improve slowly.

Social judgement: reputation is a balance sheet

This industry really is small, and information is largely transparent.

One partnership, one conference, one dispute — each settles into a label that shapes how you are seen later.

A company’s credibility is not bought with social advertising and livestreams. It accumulates every time a promise is kept.

Reputation is the most expensive compound interest in medical aesthetics.

Self-judgement: steadiness is the scarcest capability

Cash-flow pressure may be urgent, but the founder, as the core of the company, has to hold steady.

Steady emotionally, without the leaps; steady strategically, with judgement behind it.

Do not follow whatever is being said — launch today, cut prices tomorrow, white-label the day after; replace people when it does not work; swap direct sales for distributors, distributors for a master distributor; treat staff as consumables.

No owner is perfect, but anyone who has come to the front of the market must have something to commend them. Amplify your core strength. There is no need to chant slogans daily, but do try to keep a sense of order amid the anxiety.

An owner may be imperfect. An owner must be clear-eyed.

How far a company goes usually depends on how far the founder can see, and how much pressure they can bear.

The true path through this world runs through upheaval; take the long view of things.